3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
3
Unknown
2
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Sarcoma
1
Conditions
Carcinoma, Basal Cell
2
Sarcoma, Kaposi
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Interventions
Nivolumab
27
pembrolizumab
22
Ipilimumab
17
Temozolomide
13
toripalimab
12
Biopsy
10
Cyclophosphamide
9
Imiquimod
8
Dacarbazine
7
Blood Specimen Collection
7
camrelizumab
6
Chemotherapy, Adjuvant
6
trametinib
5
fludarabine
5
dabrafenib
5
atezolizumab
5
aldesleukin
5
Gene Expression Profiling
5
Cisplatin
5
Aminolevulinic Acid
5
fludarabine phosphate
4
durvalumab
4
binimetinib
4
apatinib
4
Tomography, Optical Coherence
4
Sorafenib
4
Photochemotherapy
4
Interleukin-2
4
Injections
4
Carboplatin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
daromun
×
Dermatologic
×
Clear all
NCT04362722
2023-10-10
DUNCAN
Philogen S.p.A.
Phase 2
Unknown
40 enrolled
NCT05329792
2023-10-06
IntriNSiC
Philogen S.p.A.
Phase 2
Unknown
70 enrolled